Latest | F'cast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -50.8% | -36.0% |
ROCE | n/a |
Latest | F'cast | |
---|---|---|
P/E | n/a | n/a |
PEG | n/a | n/a |
Pr/Revenue | 5.0 | 4.3 |
Pr/Book | 1.8 |
Latest | F'cast | |
---|---|---|
Revenue | 34.8% | 16.2% |
PBT | n/a | n/a |
EPS | n/a | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-20 | 1.37 | (2.55) | (0.66)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-21 | 1.23 | (3.40) | (0.73)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-22 | 1.83 | (2.57) | (0.59)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-23 | 3.19 | (6.92) | (1.54)p | n/a | n/a | n/a | n/a | 0.0% |
31-Dec-24 | 4.30 | (2.18) | (0.36)p | n/a | n/a | n/a | n/a | 0.0% |
a. Based on UK GAAP presentation of accounts - includes discontinued activities
Year Ending | Revenue (£m) | Pre-tax (£m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
---|---|---|---|---|---|---|---|---|
31-Dec-25 | 5.00 | (1.80) | (0.27)p | n/a | n/a | n/a | n/a | 0.0% |
Copyright © 2025 FactSet Research Systems Inc. All rights reserved.
Mevalone Approval in California - Powdery Mildew | 13-May-2025 | 07:00 | RNS |
Holding(s) in Company | 06-May-2025 | 12:08 | RNS |
Preliminary results for the year ended 31 Dec 2024 | 06-May-2025 | 07:00 | RNS |
No deals were found in the last 28 days.
Currency | UK Pounds |
Share Price | 4.05p |
Change Today | -0.20p |
% Change | -4.71 % |
52 Week High | 4.90 |
52 Week Low | 2.35 |
Volume | 768,905 |
Shares Issued | 533.35m |
Market Cap | £21.60m |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
No dividends found |
Time | Volume / Share Price |
16:38 | 50,000 @ 4.00p |
13:59 | 9,706 @ 4.08p |
13:35 | 94,282 @ 4.08p |
13:19 | 50,000 @ 4.00p |
13:08 | 75,000 @ 4.00p |
CFO | Alexander John Abrey |
CEO | Sean M. Smith |
You are here: research